Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shixin lozenge
- Development stage
- Phase 3
- Lead developer
- Hubei Heng'an Fulin Pharmaceutical
- Administration
- Buccal
01
Overview
Shixin lozenge (Shixin Hanpian) is a traditional Chinese medicine (TCM) developed by Hubei Hengan Pharmaceutical for the treatment of recurrent aphthous stomatitis (recurrent oral ulcers). It is specifically indicated for patients presenting with the 'stomach fire upward flaring' pattern, a TCM syndrome characterized by painful oral sores, halitosis, and thirst. The therapeutic approach involves clearing heat and purging fire to alleviate pain and accelerate the healing of oral mucosal lesions. A Phase 3 clinical trial (CTR20130821) was conducted in China to evaluate the safety and efficacy of the lozenge in adult patients compared to a placebo.
- Brand names
- Shixin lozenge
- Other names
- Shixin Hanpian视欣含片
Beyond the preview
Go deeper on Shixin lozenge.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shixin lozenge.